900 Northbrook Drive
Suite 200
Trevose, Pennsylvania 19053
May 5, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Re: Strongbridge Biopharma plc — Request for Acceleration
Registration Statement on Form S-3
File No. 333- 217555
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Strongbridge Biopharma plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 217555) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on Monday, May 8, 2017, or as soon thereafter as practicable.
The Registrant hereby authorizes each of Aron Izower, Esq. and Wendy Grasso, Esq. of Reed Smith LLP, attorneys for the Registrant, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Aron Izower at (212) 549-0393 or Wendy Grasso at (212) 549-0216.
| STRONGBRIDGE BIOPHARMA PLC |
|
|
|
|
| /s/ A. Brian Davis |
| By: A. Brian Davis |
| Chief Financial Officer |
Cc: Mary Beth Breslin and Christine Westbrook, SEC Staff